TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY
First Claim
Patent Images
1. A method for treating a cancer comprising administering to a subject in need thereof a combination comprising a BTK inhibitor and an immune checkpoint inhibitor.
9 Assignments
0 Petitions
Accused Products
Abstract
Combinations of Bruton'"'"'s tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton'"'"'s tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor.
-
Citations
20 Claims
- 1. A method for treating a cancer comprising administering to a subject in need thereof a combination comprising a BTK inhibitor and an immune checkpoint inhibitor.
-
9. A pharmaceutical combination comprising:
-
a) a BTK inhibitor; and b) an immune checkpoint inhibitor; and c) a pharmaceutically-acceptable excipient. - View Dependent Claims (10, 11, 12)
-
- 13. A method of treating an ibrutinib-resistant cancer comprising administering to a subject in need thereof a combination comprising ibrutinib and an immune checkpoint inhibitor.
-
18. A method for treating a cancer comprising administering to a subject in need thereof a combination comprising a BTK inhibitor and an inhibitor of PD-L1, PD-1, or CTLA-4.
-
19. A pharmaceutical combination comprising:
-
a) a BTK inhibitor; and b) an inhibitor of PD-L1, PD-1, or CTLA-4; and c) a pharmaceutically-acceptable excipient.
-
-
20. A method for treating an ibrutinib-resistant cancer comprising administering to a subject in need thereof a combination comprising ibrutinib and an inhibitor of PD-L1, PD-1, or CTLA-4.
Specification